journal
https://read.qxmd.com/read/37980876/vascular-endothelial-growth-factor-targeted-therapy-in-patients-with-renal-cell-carcinoma-pretreated-with-immune-checkpoint-inhibitors-a-systematic-literature-review
#1
REVIEW
Laurence Albiges, Bradley A McGregor, Daniel Y C Heng, Giuseppe Procopio, Guillermo de Velasco, Naila Taguieva-Pioger, Lidia Martín-Couce, Nizar M Tannir, Thomas Powles
INTRODUCTION: We conducted a systematic literature review to identify evidence for use of vascular endothelial growth factor (VEGF)-targeted (anti-VEGF) treatment in patients with renal cell carcinoma (RCC) following prior checkpoint inhibitor (CPI)-based therapy. METHODS: This was a PRISMA-standard systematic literature review; registered with PROSPERO (CRD42021255568). Literature searches were conducted in MEDLINE®, Embase, and the Cochrane Library (January 28, 2021; updated September 13, 2022) to identify publications reporting efficacy/effectiveness and safety/tolerability evidence for anti-VEGF treatment in patients with RCC who had received prior CPI therapy...
November 4, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37976759/recent-advances-in-genomics-and-therapeutics-in-mantle-cell-lymphoma
#2
REVIEW
Tingxun Lu, Jie Zhang, Jenna M McCracken, Ken H Young
Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle cell lymphoma (MCL). The heterogeneity observed in MCL's biology, genomics, and clinical manifestations, including indolent and aggressive forms, is intricately linked to factors such as the mutational status of the variable region of the immunoglobulin heavy chain gene, epigenetic profiling, and Sox11 expression. Several intriguing subtypes of MCL, such as Cyclin D1-negative MCL, in situ mantle cell neoplasm, CCND1/IGH FISH-negative MCL, and the impact of karyotypic complexity on prognosis, have been explored...
November 4, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37984132/molecular-profiling-in-cholangiocarcinoma-a-practical-guide-to-next-generation-sequencing
#3
REVIEW
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
Cholangiocarcinomas (CCA) are a heterogeneous group of tumors that are classified as intrahepatic, perihilar, or distal according to the anatomic location within the biliary tract. Each CCA subtype is associated with distinct genomic alterations, including single nucleotide variants, copy number variants, and chromosomal rearrangements or gene fusions, each of which can influence disease prognosis and/or treatment outcomes. Molecular profiling using next-generation sequencing (NGS) is a powerful technique for identifying unique gene variants carried by an individual tumor, which can facilitate their accurate diagnosis as well as promote the optimal selection of gene variant-matched targeted treatments...
October 31, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37988820/antibody-based-therapies-in-hodgkin-lymphoma
#4
REVIEW
Vivek S Radhakrishnan, Jemma Longley, Peter W M Johnson
Multimodality treatment approaches, with systemic therapies at their core, have made Hodgkin Lymphoma a highly curable cancer. Unmet needs remain. Resistance to therapy manifested by refractory and relapsed disease, and treatment related short- and long-term morbidity are the key challenges. Patient outcomes have improved in the recent past with the advent of novel therapies and are borne out of a better understanding of the disease biology and translational medicine. Antibody based therapies, more broadly immunotherapies, are leading the change in the way we treat this disease...
October 28, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37918169/sex-dimorphism-and-cancer-immunotherapy-may-pregnancy-solve-the-puzzle
#5
REVIEW
Francesco Maria Venanzi, Marta Bini, Antonio Nuccio, Alessandro De Toma, Matteo Lambertini, Francesca Rita Ogliari, Sara Oresti, Maria Grazia Viganò, Elena Brioschi, Maggie Polignano, Matteo Maria Naldini, Silvia Riva, Michele Ferrara, Nicola Fogale, Giuseppe Damiano, Vincenzo Russo, Michele Reni, Giulia Veronesi, Giorgia Foggetti, Fabio Conforti, Alessandra Bulotta, Roberto Ferrara
In the immunoncology era, growing evidence has shown a clear sex dimorphism in antitumor immune response with a potential impact on outcomes upon immunecheckpoint blockade (ICI) in patients with cancer. Sex dimorphism could affect tumor microenvironment composition and systemic anticancer immunity; however, the modifications induced by sex are heterogeneous. From a clinical perspective, six metanalyses have explored the role of sex in cancer patients receiving ICI with conflicting results. Environmental and reproductive factors may further jeopardize the sex-related heterogeneity in anticancer immune response...
October 26, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37862832/favorable-impact-of-therapy-management-by-an-interactive-ehealth-system-on-severe-adverse-events-in-patients-with-hormone-receptor-positive-her2-negative-locally-advanced-or-metastatic-breast-cancer-treated-by-palbociclib-and-endocrine-therapy
#6
REVIEW
Nadia Harbeck, Ronald Kates, Timo Schinköthe, Johannes Schumacher, Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, Philip Räth, Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A Fasching, Marcus Schmidt
BACKGROUND: Oral cancer medications offer advantages but also pose challenges for therapy management and adherence. An eHealth-based platform such as CANKADO can help to support therapy management by probing the patient's quality of life (QoL) continuously throughout the course of treatment. MATERIAL AND METHODS: AGO-B WSG PreCycle (NCT03220178) is a multicenter, randomized phase IV intergroup trial evaluating the impact of eHealth-based Patient-Reported Outcome (ePRO) assessment on QoL in patients with hormone receptor-positive (HR + )/HER2-negative (HER2-) advanced breast cancer treated with palbociclib and endocrine therapy...
October 18, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37879247/evolution-of-the-hif-targeted-therapy-in-clear-cell-renal-cell-carcinoma
#7
REVIEW
Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, affecting hundreds of thousands of people worldwide and can affect people of any age. The pathogenesis of ccRCC is most commonly due to biallelic loss of the tumor suppressor gene VHL. VHL is the recognition subunit of an E3-ubiquitin-ligase-complex essential for degradation of the hypoxia-inducible factors (HIF) 1α and 2α. Dysfunctional degradation of HIF results in overaccumulation, which is particularly concerning with the HIF2α subunit...
October 15, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37864956/esr1-mutations-in-hr-her2-metastatic-breast-cancer-enhancing-the-accuracy-of-ctdna-testing
#8
REVIEW
Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Malapelle
Activating mutations of the estrogen receptor alpha gene (ESR1) are common mechanisms of endocrine therapy (ET) resistance in hormone receptor-positive (HR + )/Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic breast cancer (MBC). Recent clinical findings emphasize that both old and new generations of selective ER degraders (SERDs) demonstrate enhanced clinical effectiveness in patients with MBC who have detectable ESR1 mutations via liquid biopsy. This stands in contrast to individuals with MBC carrying these mutations and undergoing conventional endocrine monotherapies like aromatase inhibitors (AIs)...
December 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37871463/the-prognostic-potential-of-cdx2-in-colorectal-cancer-harmonizing-biology-and-clinical-practice
#9
REVIEW
Jordi Badia-Ramentol, Francisco Gimeno-Valiente, Elena Duréndez, Carolina Martínez-Ciarpaglini, Jenniffer Linares, Mar Iglesias, Andrés Cervantes, Alexandre Calon, Noelia Tarazona
Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome after current forms of chemotherapy. While reflecting the increasing complexity of CRC, the clinical application of molecular biomarkers provides information that can be utilized to guide therapeutic strategies. Among these, caudal-related homeobox transcription factor 2 (CDX2) emerges as a biomarker of both prognosis and relapse after therapy...
October 12, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37837788/engineering-strategies-to-optimise-adoptive-cell-therapy-in-ovarian-cancer
#10
REVIEW
Catarina Guerra, Milena Kalaitsidou, Gray Kueberuwa, Robert Hawkins, Richard Edmondson
Ovarian cancer is amongst the ten most common cancer types in women, and it is one of the leading causes of death. Despite the promising results of targeted therapies, including anti-angiogenic agents and poly (ADP-ribose) polymerase inhibitors (PARPi), the majority of patients will relapse and develop treatment resistance, implying that novel therapeutic strategies are required. Adoptive cell therapy (ACT) refers to the process by which autologous immune cells are used to eliminate cancer. Examples include tumour infiltrating lymphocytes (TILs), T cells genetically engineered with T cell receptors (TCR), or chimeric antigen receptor (CAR)-T cells...
October 5, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37769435/regulatory-t-cells-in-gastric-cancer-key-controllers-from-pathogenesis-to-therapy
#11
REVIEW
Ion Negura, Mariana Pavel-Tanasa, Mihai Danciu
Gastric cancer (GC) is a highly aggressive malignancy that remains a significant contributor to cancer-related mortality worldwide, despite a decline in incidence in recent years. Early-stage GC poses a diagnostic challenge due to its asymptomatic nature, leading to poor prognoses for most patients. Conventional treatment approaches, including chemotherapy and surgery, have shown limited efficacy in improving outcomes for GC patients. The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy, yielding durable responses across various malignancies...
September 23, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37713972/patient-reported-outcome-measure-to-implement-routine-assessment-of-cancer-survivors-unmet-needs-an-overview-of-reviews-and-cosmin-analysis
#12
REVIEW
Angela Contri, Sara Paltrinieri, Martina Torreggiani, Maria Chiara Bassi, Elisa Mazzini, Monica Guberti, Isabella Campanini, Luca Ghirotto, Stefania Fugazzaro, Stefania Costi
As the number of cancer survivors (CSs) is increasing worldwide, providing services relevant to the specific, unmet needs of these individuals is crucial. There are currently various patient-reported outcome measures (PROMs) whose aim is to identify the unmet needs of CSs. Still, limited guidance supports healthcare providers in choosing the most valid and reliable PROMs for this purpose. We conducted this overview of systematic reviews (SRs) on the psychometric properties of PROMs addressing the unmet needs of adult CSs suffering from non-cutaneous cancers...
September 9, 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37939446/theranostic-biomarkers-and-parp-inhibitors-effectiveness-in-patients-with-non-brca-associated-homologous-recombination-deficient-tumors-still-looking-through-a-dirty-glass-window
#13
REVIEW
Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, Chiara Brando, Valerio Gristina, Daniela Cancelliere, Alessia Pivetti, Silvia Contino, Emilia Di Giovanni, Nadia Barraco, Marco Bono, Ambra Giurintano, Tancredi Didier Bazan Russo, Andrea Gottardo, Sofia Cutaia, Erika Pedone, Marta Peri, Lidia Rita Corsini, Daniele Fanale, Antonio Galvano, Giovanni Scambia, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan
Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) deleterious variants were the first and, still today, the main biomarkers of poly(ADP)ribose polymerase (PARP)-inhibitors (PARPis) benefit. The recent, increased, numbers of individuals referred for counseling and multigene panel testing, and the remarkable expansion of approved PARPis, not restricted to BRCA1/BRCA2-Pathogenic Variants (PVs), produced a strong clinical need for non-BRCA biomarkers. Significant limitations of the current testing and assays exist...
December 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37925878/resistance-mechanism-to-fibroblast-growth-factor-receptor-fgfr-inhibitors-in-cholangiocarcinoma
#14
REVIEW
Angela Lamarca, Lorena Ostios, Mairéad G McNamara, Carlos Garzon, Jack P Gleeson, Julien Edeline, Ana Herrero, Richard A Hubner, Victor Moreno, Juan W Valle
Precision medicine is a major achievement that has impacted on management of patients diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular profiling of CCA has identified targetable alterations, such as fibroblast growth factor receptor-2 (FGFR-2) fusions, and has thus led to the development of a wide spectrum of compounds. Despite favourable response rates, especially with the latest generation FGFRi, there are still a proportion of patients who will not achieve a radiological response to treatment, or who will have disease progression as the best response...
December 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37864955/axl-a-new-player-in-resistance-to-her2-blockade
#15
REVIEW
Anna Adam-Artigues, Enrique J Arenas, Joaquín Arribas, Aleix Prat, Juan Miguel Cejalvo
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. Despite targeted anti-HER2 therapy has improved outcomes and is the current standard of care, resistance emerge in some patients, requiring additional therapeutic strategies. Several mechanisms, including the upregulation of receptors tyrosine kinases such as AXL, are involved in resistance...
December 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37862833/revisiting-the-concept-of-neoadjuvant-and-induction-therapy-in-head-and-neck-cancer-with-the-advent-of-immunotherapy
#16
REVIEW
Davide Smussi, Davide Mattavelli, Alberto Paderno, Cristina Gurizzan, Luigi Lorini, Chiara Romani, Eliana Bignotti, Alberto Grammatica, Marco Ravanelli, Paolo Bossi
The treatment of locally advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC) is based on surgery followed by (chemo)radiation or on curative (chemo)radiation, depending on site and stage. Despite optimal locoregional treatment, about 50% of patients recur, with a huge impact on prognosis and substantial morbidity. The advent of immunotherapy (IT) with immune checkpoint inhibitors (ICIs) changed the paradigm of systemic treatment for recurrent/metastatic (RM) disease, showing activity, efficacy, and safety in both platinum-resistant and platinum-naïve patients...
December 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37797348/a-comprehensive-overview-of-the-heterogeneity-of-egfr-exon-20-variants-in-nsclc-and-pre-clinical-activity-to-currently-available-treatments
#17
REVIEW
Fenneke Zwierenga, Bianca A M H van Veggel, Anke van den Berg, Harry J M Groen, Lili Zhang, Matthew R Groves, K Kok, E F Smit, T Jeroen N Hiltermann, Adrianus J de Langen, Anthonie J van der Wekken
Activating EGFR mutations are commonly observed in non-small cell lung cancer (NSCLC). About 4-10 % of all activating epidermal growth factor receptor (EGFR) mutations are heterogenous in-frame deletion and/or insertion mutations clustering within exon 20 (EGFRex20+). NSCLC patients with EGFRex20+ mutations are treated as a single disease entity, irrespective of the type and location of the mutation. Here, we provide a comprehensive assessment of the literature reporting both in vitro and clinical drug sensitivity across different EGFRex20+ mutations...
November 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37751658/estrogen-deprivation-effects-of-endocrine-therapy-in-breast-cancer-patients-incidence-management-and-outcome
#18
REVIEW
Linda Cucciniello, Giovanna Garufi, Rossana Di Rienzo, Claudia Martinelli, Giuliana Pavone, Mario Giuliano, Grazia Arpino, Filippo Montemurro, Lucia Del Mastro, Michelino De Laurentiis, Fabio Puglisi
Endocrine therapy is one of the standard adjuvant treatments to reduce the risk of recurrence and mortality in patients with hormone receptor positive early breast cancer. Despite its proven efficacy, ET side effects, which persist over time even if low grade, may deteriorate quality of life. During follow-up visits, emphasis is generally placed on the risk of disease recurrence, while the topic of ET side effects is commonly neglected and discussed only briefly. This could lead to poor adherence to therapy and early treatment discontinuation, resulting in worse survival outcomes...
November 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37738712/a-systematic-review-of-recent-phase-ii-trials-in-refractory-or-recurrent-osteosarcoma-can-we-inform-future-trial-design
#19
REVIEW
Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, Marie-Cécile le Deley, Natasha van Eijkelenburg, Pascaline Boudou-Rouquette, Séverine Risbourg, Sandra J Strauss, Emanuela Palmerini, Kjetil Boye, Leo Kager, Stefanie Hecker-Nolting, Antonin Marchais, Nathalie Gaspar
BACKGROUND/OBJECTIVE: To analyze changes in recurrent/refractory osteosarcoma phase II trials over time to inform future trials in this population with poor prognosis. METHODS: A systematic review of trials registered on trial registries between 01/01/2017-14/02/2022. Comparison of 98 trials identified between 2003 and 2016. Publication search/analysis for both periods, last update on 01/12/2022. RESULTS: Between 2017 and 2022, 71 phase-II trials met our selection criteria (19 osteosarcoma-specific trials, 14 solid tumor trials with and 38 trials without an osteosarcoma-specific stratum)...
November 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37734178/managing-postoperative-biochemical-relapse-in-prostate-cancer-from-the-perspective-of-the-francophone-group-of-urological-radiotherapy-gfru
#20
REVIEW
Loic Ah-Thiane, Paul Sargos, Olivier Chapet, Marjory Jolicoeur, Mario Terlizzi, Carl Salembier, Jihane Boustani, Célia Prevost, Sonya Gaudioz, Talar Derashodian, Samuel Palumbo, Olivier De Hertogh, Gilles Créhange, Thomas Zilli, Stéphane Supiot
Up to 50% of patients treated with radical surgery for localized prostate cancer may experience biochemical recurrence that requires appropriate management. Definitions of biochemical relapse may vary, but, in all cases, consist of an increase in a PSA without clinical or radiological signs of disease. Molecular imaging through to positron emission tomography has taken a preponderant place in relapse diagnosis, progressively replacing bone scan and CT-scan. Prostate bed radiotherapy is currently a key treatment, the action of which should be potentiated by androgen deprivation therapy...
November 2023: Cancer Treatment Reviews
journal
journal
25655
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.